Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: Results from the DOPPS

Kidney International

Volumn 84, Issue 3, 2013, Pages 600-608

  Sood, Manish M ^a   Larkina, Maria ^b   Thumma, Jyothi R ^b   Tentori, Francesca ^b,c   Gillespie, Brenda W ^d   Fukuhara, Shunichi ^e   Mendelssohn, David C ^f   Chan, Kevin ^g   De Sequera, Patricia ^h   Komenda, Paul ^a   Rigatto, Claudio ^a   Robinson, Bruce M ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e KYOTO UNIVERSITY   (Japan)

^f UNIVERSITY OF TORONTO   (Canada)

^g FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^h HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

anticoagulation; dialysis; end stage renal disease; mortality risk; survival

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DICOUMAROL; DIPYRIDAMOLE; FLUINDIONE; HISTAMINE H2 RECEPTOR ANTAGONIST; PENTOXIFYLLINE; PHENPROCOUMON; PROTON PUMP INHIBITOR; TICLOPIDINE; WARFARIN;

ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

AGED; ANTICOAGULANTS; ASPIRIN; COHORT STUDIES; FEMALE; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 84883450078     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.170     Document Type: Article

References (47)

1. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001; 104: 2118-2150.
2. Schulman S, Beyth RJ, Kearon C et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 257S-298S.
3. Singer DE, Albers GW, Dalen JE et al. American College of Chest, Physicians antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 546S-592S.
4. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
5. Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719.
6. Ruiz-Gimenez N, Suarez C, Gonzalez R et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE registry. Thromb Haemost 2008; 100: 26-31.
7. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102: 268-278.
8. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
9. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19: 317-322.
10. Gangji AS, Sohal AS, Treleaven D et al. Bleeding in patients with renal insufficiency: A practical guide to clinical management. Thromb Res 2006; 118: 423-428.
11. Holden RM, Harman GJ, Wang M et al. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 105-110.
12. Limdi NA, Beasley TM, Baird MF et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20: 912-921.
13. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding rates. Am J Kidney Dis 2007; 50: 433-440.
14. Kawamura M, Fijimoto S, Hisanaga S et al. Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis 1998; 31: 991-996.
15. Fabbian F, Catalano C, Lambertini D et al. Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin Nephrol 2000; 54: 234-239.
16. Vazquez E, Sanchez-Perales C, Borrego F et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000; 140: 886-890.
17. Abbott KC, Trespalacios FC, Taylor AJ et al. Atrial fibrillation in chronic dialysis patients in the United States: Risk factors for hospitalization and mortality. BMC Nephrol 2003; 4: 1.
18. Genovesi S, Pogliani D, Faini A et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005; 46: 897-902.
19. Ethier J, Bragg-Gresham JL, Piera L et al. Aspirin prescription and outcomes in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2007; 50: 602-611.
20. Quinn RR, Naimark DM, Oliver MJ et al. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation?. A cost-utility analysis. Am J Kidney Dis 2007; 50: 421-432.
21. Genovesi S, Vincenti A, Rossi E et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008; 51: 255-262.
22. Wasse H. Catheter-related mortality among ESRD patients. Semin Dial 2008; 21: 547-549.
23. Willms L, Vercaigne LM. Does warfarin safely prevent clotting of hemodialysis catheters?. a review of efficacy and safety. Semin Dial 2008; 21: 71-77.
24. Sozio SM, Armstrong PA, Coresh J et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: The choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 2009; 54: 468-477.
25. Wizemann V, Tong L, Satayathum S et al. Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77: 1098-1106.
26. Seliger SL, Gillen DL, Longstreth WT et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64: 603-609.
27. Phillips KW, Dobesh PP, Haines ST. Considerations in using anticoagulant therapy in special patient populations. Am J Health Syst Pharm 2008; 65: S13-S21.
28. Chan KE, Lazarus JM, Thadhani R et al. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20: 872-881.
29. Chan KE, Lazarus JM, Thadhani R et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20: 2223-2233.
30. Tentori F, Zhang J, Li Y et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2012; 27: 4180-4188.
31. Robinson BM, Tong L, Zhang J et al. Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2012; 82: 570-580.
32. Pisoni RL, Arrington CJ, Albert JM et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: An instrumental variable analysis. Am J Kidney Dis 2009; 53: 475-491.
33. McFarlane PA, Pisoni RL, Eichleay MA et al. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int 2010; 78: 215-223.
34. Hecking M, Karaboyas A, Saran R et al. Predialysis serum sodium level, dialysate sodium, and mortality in maintenance hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2012; 59: 238-248.
35. Sood MM, Komenda P, Sood AR et al. The intersection of risk and benefit: Is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?. Chest 2009; 136: 1128-1133.
36. Lo DS, Rabbat CG, Clase CM. Thromboembolism and anticoagulant management in hemodialysis patients: A practical guide to clinical management. Thromb Res 2006; 118: 385-395.
37. Toyoda K, Fujii K, Fujimi S et al. Stroke in patients on maintenance hemodialysis: A 22-year single-center study. Am J Kidney Dis 2005; 45: 1058-1066.
38. Yang JY, Lee TC, Montez-Rath ME et al. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol 2012; 23: 495-506.
39. Rockx MA, Sood MM. A necrotic skin lesion in a dialysis patient after the initiation of warfarin therapy: A difficult diagnosis. J Thromb Thrombolysis 2010; 29: 130-133.
40. Mazhar AR, Johnson RJ, Gillen D et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60: 324-332.
41. Wilmer WA, Magro CM. Calciphylaxis: Emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002; 15: 172-186.
42. Holden RM, Booth SL. Vascular calcification in chronic kidney disease: The role of vitamin K. Nat Clin Pract Nephrol 2007; 3: 522-523.
43. Pilkey RM, Morton AR, Boffa MB et al. Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 2007; 49: 432-439.
44. Pisoni RL, Gillespie BW, Dickinson DM et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): Design, data elements, and methodology. Am J Kidney Dis 2004; 44: 7-15.
45. Young EW, Goodkin DA, Mapes DL et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study. Kidney Int 2000 57 suppl 74: S-74-S-81.
46. Miskulin D, Bragg-Gresham J, Gillespie BW et al. Key comorbid conditions that are predictive of survival among hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1818-1826.
47. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: E89S-e119S.